Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
In this section, we usually try to help investors determine whether BioLargo is trading at an attractive price based on the cash flow it is expected to produce in the future. But as BioLargo has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.
This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis. You can see them here.
Show me the analysis anyway
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
BioLargo. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
BioLargo's earnings available for a low price, and how does
this compare to other companies in the same industry?
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as BioLargo has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.
Show me the analysis anyway
The future performance of a company is measured in the same way as past
performance, by looking at estimated
and how much profit it is expected to make.
Future estimates come from
professional analysts. Just like forecasting the weather, they don’t always get
Expected Chemicals industry annual growth in earnings.
Earnings growth vs Low Risk Savings
expected to grow at an
Unable to compare BioLargo's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
Unable to compare BioLargo's earnings growth to the United States of America market average as no estimate data is available.
Unable to compare BioLargo's revenue growth to the United States of America market average as no estimate data is available.
Unable to determine if BioLargo is high growth as no earnings estimate data is available.
Unable to determine if BioLargo is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access BioLargo's filings and announcements here.
BioLargo's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Mr. Dennis P. Calvert serves as the Chairman of the Board at BioLargo, Inc. and has been its Chief Executive Officer and President since June 28, 2002. Mr. Calvert has an extensive entrepreneurial background as an operator, investor and Consultant. He also serves as President, Chief Executive Officer and Chairman BioLargo Life Technologies, Inc. and BioLargo Water U.S.A., Inc. and chairman of the board of directors of Odor-No-More, Inc., Clyra Medical Technologies, Inc. and BioLargo Water, Inc. (Canada). He served as Interim Chief Financial Officer of BioLargo, Inc. since March 2003, Chief Financial Officer from March 2003 to January 2008 and as its Corporate Secretary from September 12, 2002 to March 1, 2003. From June 2002 to September 2002, he served as President of Med Wireless, Inc. In 1998, Mr. Calvert founded Utelecom Communications, Inc. and served as its President, where he led the acquisition of four companies and secured a line of credit for $7.5 million dollars. He served as a Manager of Beep of Free.com, LLC since 2000. From 1990 to 1996, he served as Head of Mergers and Acquisitions of Medical Asset Management, Inc. During his tenure, he participated in more than 50 acquisitions and served in numerous positions with Medical Asset Management, Inc. Mr. Calvert founded Merritt Hawkins and Associates and served as its Officer from 1987 to 1990. Earlier, he served as Top Producing Sales Associate of Jackson and Coker, Inc. and served as a Sales Associate of Diamond Shamrock Chemicals Company from 1985 to 1986. Mr. Calvert founded ZZYZX Technologies, Inc. and served as its Chairman. He has been a Director of Utelecom Communications, Inc. since 1998 and BioLargo, Inc. since June 28, 2002. He also serves on the board of directors at The Maximum Impact Foundation. He serves as a member of the Advisory Council for Wake Forest University’s Center for Innovation, Creativity and Entrepreneurship, and as a Director of Cleantech OC. He joined the Board of Directors of Tilly’s Life Center. He is also an Eagle Scout. He has been an active coach in youth sports organizations and ministry activity in his home community. Mr. Calvert holds a BA degree in Economics from Wake Forest University, where he was a varsity basketball player on full scholarship. He studied at Columbia University and Harding University. He was an honor student in high school with numerous leadership awards.
Dennis's compensation has increased whilst company is loss making.
Dennis's remuneration is higher than average for companies of similar size in United States of America.
Management Team Tenure
Average tenure and age of the
management team in years:
The average tenure for the BioLargo management team is over 5 years, this suggests they are a seasoned and experienced team.
Chief Financial Officer
VP of Operations
Chief Science Officer & Director
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The tenure for the BioLargo board of directors is about average.
BioLargo, Inc. operates as a science, technology, and environmental engineering company. Its platform technologies include Advanced Oxidation System (AOS), CupriDyne, and Isan. The company offers odor and volatile organic compound control products, AOS water treatment technologies, and technologies in the medical and dental fields, as well as professional engineering services. It provides commercial, household, and personal care products, including an animal-bedding additive that controls odor and moisture; and liquid odor control products under the Odor-No-More, Nature’s Best Science, Deodorall, and NBS brand names. BioLargo, Inc. was founded in 1989 and is based in Westminster, California.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.